

## Anti-B7-H1/PD-L1/CD274 Antibody (Garivulimab)

### Introduction

Garivulimab (BGB-A333) is a humanized IgG1 variant monoclonal antibody that specifically targets and binds to PD-L1. Garivulimab selectively blocks the interaction between PD-L1 and PD-1 and has anti-tumor activity.

### Product parameters

Alternative Names	BGB-A333
Target Accession	Q9NZQ7
Target	B7-H1 / PD-L1 / CD274
CAS number	2342597-81-1
Molecular Weight	144.3 kDa
Host	CHO
Reactivity	Human
Conjugation	Unconjugated
Form	Liquid
Concentration	See label
Buffer System	100 mM Pro 20 mM Arg pH 5.0. No preservative!
Clonality	Monoclonal
Purification	Protein A
Isotype	IgG1
Application	ELISA, FACS, Kinetics, Functional assay, Animal Model
Biological activity	-
Endotoxin	Less than 0.1 EU/ug determined by LAL method.
Sterilization	0.2 µM filtered
Reconstitution	For reconstitution, we recommend adding sterile, distilled water to achieve a final antibody concentration. Gently shake it to solubilize the protein completely. Do not vortex.
Shipping	Dry ice
Storage	-80°C
Expiration Date	2 years
Note	Please avoid freeze-thaw cycles.

## ■ Note

1. This product is for scientific research use only.



**APExBIO Technology**

**[www.apexbt.com](http://www.apexbt.com)**

7505 Fannin street, Suite 410, Houston, TX 77054.

Tel: +1-832-696-8203 | Fax: +1-832-641-3177 | Email: [info@apexbt.com](mailto:info@apexbt.com)

